Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Zacks News
Mesa Labs (MLAB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Mesa Labs (MLAB) closed at $193.84 in the latest trading session, marking a +0.96% move from the prior day.
Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Mesa Labs (MLAB) closed at $190.51 in the latest trading session, marking a +0.93% move from the prior day.
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
Mesa Labs (MLAB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Mesa Labs (MLAB) closed the most recent trading day at $178.79, moving +1.53% from the previous trading session.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Buy Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Mesa Labs (MLAB)
by Kevin Cook
After Q2 results, EPS estimates soar 39% as revenues grow 24% on strong M&A strategies
3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is an overhang.
Earnings Estimates Moving Higher for Mesa Labs (MLAB): Time to Buy?
by Zacks Equity Research
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bear of the Day: Fresenius Medical (FMS)
by David Bartosiak
Profit estimates are moving in the wrong direction.
Mesa Labs (MLAB) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 107.19% and 10.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -40% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 18.09% and 6.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -40% and 60.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q3 Earnings Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -19.05% and 13.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022